On the other hand, the primary tumor type observed after tamoxifen treatment in Tp53−/− mice were thymic lymphomas (98% incidence), and deletion of Prl2 in this model drastically reduced the incidence of thymic lymphomas (∼62%; Fig. 3C). This evidence concerns the gene TP53 and thymus lymphoma.